NCT03808805

Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: University Hospital, Brest · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.

Detailed description

Identification of patients with myeloproliferative neoplasms and aquagenic pruritus. Evaluation of the intensity of the aquagenic pruritus. Patients with value \>5/10 on the VAS (Visual Analogue Scale ) are proposed to participate to the protocole. Randomization between the two treatments. Duration of the treatment : 14 days. Regular evaluation of efficacity of the drugs (questionnaires). Evaluations will stop 2 months after the last intake. Blood samples will be collected before and after the intakes to study cytokine and neuropeptide levels.

Conditions

• Myeloproliferative Disorder
• Aquagenic Pruritus

Interventions

Type	Name	Description
DRUG	Aprepitant 80 mg	oral therapy - daily dose - 14 days
DRUG	Hydroxyzine 25mg	oral therapy - daily dose - 14 days
DRUG	Placebo of Hydroxyzine	oral therapy - daily dose - 14 days
DRUG	Placebo of Aprepitant	oral therapy - daily dose - 14 days

Timeline

• Start date: 2019-04-16
• Primary completion: 2023-09-01
• Completion: 2024-08-22
• First posted: 2019-01-18
• Last updated: 2025-12-03

Locations

11 sites across 1 country: France